This section describes antiretroviral (ARV) drugs and drug combinations that either are not recommended for use in ARV-naive children or lack sufficient data to recommend their use in ARV-naive children. Although many ARV agents and combinations are available, some are not recommended for use as part of an initial regimen in ARV-naive children, but they …
Regimens Not Recommended for Use in ARV-Naive Children Read More »
AU Comment: Monitoring children on ART Height and weight should also be monitored routinely, with drug doses adjusted according to changes in weight. Weight and BMI monitoring are particularly important in children commencing on or changing to ART regimens containing integrase inhibitors (especially bictegravir and dolutegravir) and/or tenofovir alafenamide Reference: Sax et al 2020. AU Comment: Phenotypic resistance testing Phenotypic …
Clinical and Laboratory Monitoring of Pediatric HIV Infection Read More »
AU Comment: Infant virologic diagnostic testing Australian clinicians may prefer to follow the BHIVA guidelines, which recommend virologic diagnostic testing within the first 48 hours (and prior to hospital discharge), at 2 weeks after cessation of antiretroviral prophylaxis, and at 8 weeks after cessation of antiretroviral prophylaxis. In the setting of breastfeeding, infants are recommended to …
AU comment: Maternal HIV testing Expedite testing of mother as soon as practicable and if test is positive, a) intrapartum antiretroviral (ARV) prophylaxis should be initiated immediately if mother is still in labour and b) infants should receive an ARV regimen that is appropriate for infants who are at higher risk of perinatal HIV transmission as soon as practicable, pending results …
Maternal HIV Testing and Identification of Perinatal HIV Exposure Read More »
The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed and updated the text and references of previous versions of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection published on April 11, 2022, and October 11, 2022. The Australian HIV Paediatrics Guidelines Committee reviewed these updates …
The Australian Commentary to the DHHS Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection has been prepared by the ASHM HIV Paediatric Guidelines Committee along with external contributors (see: Contributors). The US DHHS has agreed to this adoption and adaptation process. The ASHM HIV Paediatric Guidelines Committee provides the commentary and reviews …
Name Entity Relationship Benefit to Individual Benefit to Institution Rick Varma (chair) None N/A Andrew Grulich Seqirus Grant/grants pending X Cancer Council NSW Grant/grants pending X American Foundation for AIDS Research Grant/grants pending X Gilead Educational presentations X Merck Educational presentations X NHMRC Travel expenses X Cure Cancer Australia Advisory Board Member X NSW Ministry …
The Australian Commentary has been written and reviewed by members of the ASHM Sub-Committee for Guidance on HIV Management in Australia. The members of the Sub-Committee are listed below: Name Affiliation Position Rick Varma Chair appointed by ASHM Board Senior Staff Specialist (Sexual Health) and Clinical Services Manager, Sydney Sexual Health Adam Bartlett Invited Member …
LINKS TO TABLES HERE Table 1: Coformulated and Copackaged Antiretroviral Regimens AU Commentary: Table 1 Stribild – this product has been removed from the market in Australia, access to generic equivalents are NOT available. Atripla – this product has been removed from the market in Australia– access to generic equivalent is available and reimbursed via …
Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM